Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13690053 | 0.88 | HPGD (0.64) | HPGDCYP1A2CYP2C19ALDH1A1MEN1 | |
| SCHEMBL13602368 | 0.85 | PKM (0.49) | HPGDCYP1A2CYP2C19ALDH1A1MEN1 | |
| SCHEMBL13602444 | 0.84 | MAPT (0.58) | HPGDCYP1A2CYP2C19ALDH1A1MEN1 | |
| SCHEMBL11594362 | 0.81 | CYP1A2 (0.68) | HPGDCYP1A2CYP2C19ALDH1A1MEN1 | |
| SCHEMBL31087272 | 0.81 | NPC1 (0.59) | ALDH1A1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL13689825 | 0.79 | ALDH1A1 (0.43) | HPGDCYP1A2CYP2C19ALDH1A1MEN1 | |
| SCHEMBL11155741 | 0.78 | PBRM1 (0.58) | HPGDCYP1A2CYP2C19ALDH1A1RAB9A | |
| SCHEMBL28729711 | 0.77 | CYP1A2 (0.53) | HPGDCYP1A2CYP2C19ALDH1A1MEN1 | |
| SCHEMBL9833874 | 0.77 | CYP1A2 (0.77) | HPGDCYP1A2CYP2C19ALDH1A1MEN1 | |
| SCHEMBL1514283 | 0.77 | HPGD (0.77) | HPGDCYP1A2CYP2C19ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1214292-B1 | TYROSINE DERIVATIVES | GENENTECH INC (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005113003-A2 | METHOD FOR AUGMENTING B CELL DEPLETION | GENENTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | VCAM1, ICAM1, ITGB4 | HPGD 3620/4885CYP1A2 2883/4885CYP2C19 2320/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | HPGD 3099/4885CYP1A2 3933/4885CYP2C19 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.